Diabetes, Metabolic Syndrome and Obesity (Nov 2024)
Change in Cardiometabolic Health Following Participation in Cardiac Rehabilitation for Coronary Heart Disease: Effect Modification by Metabolic Syndrome Status
Abstract
Joshua Garfein,1 Elizabeth A Gnatiuk,1,2 Eric J Brandt,1,3 Chih-Wen Pai,1 Joseph Bryant,1 Eva Kline-Rogers,1 Samantha Fink,1 Melvyn Rubenfire1 1Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; 2Experimental Medicine Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 3Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USACorrespondence: Melvyn Rubenfire, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, 24 Frank Lloyd Wright Dr, Lobby A., Ann Arbor, MI, 48106-0363, USA, Tel +1 734 998 7411, Fax +1 734 998 7456, Email [email protected]: To investigate changes in cardiometabolic risk factors after completion of cardiac rehabilitation (CR) for coronary heart disease (CHD) and ascertain whether the magnitude of improvement in cardiometabolic health differs between those with and without metabolic syndrome (MetS).Methods: In this observational cohort study, data were analyzed from 1984 patients enrolled in CR at the University of Michigan between 2011-01-01 and 2020-02-29 for the indication of CHD. Patient characteristics were collected from standardized health questionnaires and during CR intake evaluations. Cardiometabolic biomarkers were recorded from baseline laboratory data and re-examined upon completion of CR. Differences in baseline patient characteristics by MetS status were compared using chi-square tests. Wilcoxon rank-sum tests were used to compare baseline differences, and signed-rank tests were used to evaluate the change in variables between baseline and completion of CR. The difference of change by MetS status was assessed using difference-in-differences regression models.Results: Of the 1984 patients, 1070 (53.9%) met the criteria for MetS at baseline, of which 770 were male (72.0%). Those with MetS lost 1.43 pounds more (95% CI: 0.56, 2.31, P = 0.001), experienced a 0.21 larger drop in body mass index (95% CI: 0.03, 0.37, P = 0.02), and had a 0.31 greater reduction in waist circumference (95% CI: 0.08, 0.54, P = 0.008). Difference-in-differences regression models revealed those with MetS experienced a greater reduction in triglycerides and fasting glucose, with a difference of change of − 8.70 for triglycerides (95% CI: − 15.04, − 2.37, P = 0.007) and − 5.48 for glucose (95% CI: − 10.44, − 0.53, P = 0.03). There was no significant difference in the change in HDL-C or LDL-C for MetS status.Conclusion: Compared to those without MetS, patients with MetS experienced a comparable or greater benefit from CR, particularly with respect to improvements in MetS components.Keywords: chronic disease management, coronary heart disease, cardiometabolic risk factors, cardiovascular disease